Effect of triple therapy in patients with asthma-COPD overlap .

Published on Aug 1, 2019
· DOI :10.5414/CP203382
Yoshihisa Ishiura17
Estimated H-index: 17
(Kansai Medical University),
Masaki Fujimura53
Estimated H-index: 53
(Kanazawa University)
+ 6 AuthorsShosaku Nomura52
Estimated H-index: 52
(Kansai Medical University)
Sources
Abstract
OBJECTIVE: Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is of increasing interest because ACO patients have significantly worse outcomes, leading to greater social and economic burdens compared with asthma or COPD alone. Some guidelines for ACO recommend triple therapy with inhaled corticosteroids, long-acting β2 agonists, and long-acting muscarinic antagonists. However, this approach is based on extrapolating data from patients with asthma or COPD alone. Therapeutic studies for ACO have not previously been conducted. MATERIALS AND METHODS: A 12-week, randomized, open-label cross-over pilot study was conducted in 17 ACO patients to evaluate the effect of umeclidinium (UMEC) 62.5 µg once-daily added to fluticasone furoate/vilanterol (FF/VI) 200/25 µg once-daily. A 4-week run-in, a first and a second 4-week treatment period were included. Respiratory function, respiratory impedance, fractional exhaled nitric oxide, COPD assessment test, and asthma control test scores were evaluated 0, 4, and 8 weeks after randomization. RESULTS: Mean values of post-bronchodilator forced expiratory volume in 1 second as a percentage of the predicted value (%FEV1), after UMEC was added to FF/VI, were significantly higher than after the run-in (p < 0.01). Mean values of resonant frequency during inspiration (Fres), after UMEC was added to FF/VI, were significantly lower than after the run-in (p < 0.01). CONCLUSION: Adding UMEC to FF/VI provides greater improvement in lung function, indicating that triple therapy is a suitable regular treatment for ACO.
📖 Papers frequently viewed together
25 Citations
310 Citations
82 Citations
References37
Newest
#1Alida Benfante (University of Palermo)H-Index: 13
#2Fulvio BraidoH-Index: 31
Last. Nicola Scichilone (University of Palermo)H-Index: 40
view all 3 authors...
5 CitationsSource
#1David A. LipsonH-Index: 26
#2Frank BarnhartH-Index: 6
Last. Steven PascoeH-Index: 10
view all 18 authors...
Abstract Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid–LABA or LAMA–LABA), are uncertain. Methods In this randomized trial involving 10,355 patients with COPD, we compared 52 weeks of a once-daily combination of fluticasone furoate (an inhaled glucocorticoid) at a dose of 100 μg, ...
440 CitationsSource
#1Yoshihisa Ishiura (Kansai Medical University)H-Index: 17
#2Masaki FujimuraH-Index: 53
Last. Kazuo Kasahara (Kanazawa University)H-Index: 28
view all 7 authors...
Background Asthma in the elderly population has been focused because it affects quality of life and results in a higher hospitalization rate and mortality. Fluticasone furoate (FF)/vilanterole (VI) is a novel inhaled corticosteroids (ICS)/long-acting β2 agonist (LABA) combination being developed for once-daily administration for asthma with greater anti-inflammatory activity and longer duration of bronchidilation. The ElliptaTM dry powder inhaler (DPI) has also been available as a new device wit...
7 CitationsSource
#1Afisi S. Ismaila (McMaster University)H-Index: 21
#2Ruby BirkH-Index: 6
Last. David A. Lipson (UPenn: University of Pennsylvania)H-Index: 26
view all 9 authors...
Introduction Chronic obstructive pulmonary disease is associated with a high healthcare resource and cost burden. Healthcare resource utilization was analyzed in patients with symptomatic chronic obstructive pulmonary disease at risk of exacerbations in the FULFIL study. Patients received either once-daily, single inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) 100 µg/62.5 µg/25 µg or twice-daily dual inhaled corticosteroid/long-acting beta agonist therapy (budesonide/formot...
9 CitationsSource
BACKGROUND: Asthma and chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is an increasingly recognized phenotype. Few randomized clinical trials have been conducted in patients with ACOS; therefore, scientific evidence concerning ACOS is scarce and a therapeutic approach remains unclear. The aim of this study was to evaluate current treatment trends for patients with ACOS, identified as those with a dual definition of asthma and COPD, in a real-world COPD cohort. METHODS: Data...
18 CitationsSource
#1Nguyen Van ThoH-Index: 8
#2Hye Yun Park (SMC: Samsung Medical Center)H-Index: 24
Last. Yasutaka Nakano (Shiga University of Medical Science)H-Index: 46
view all 3 authors...
Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is characterized by persistent airflow limitation with several features usually associated with asthma and several features usually associated with COPD. ACOS may be a special phenotype of a spectrum of chronic obstructive airway diseases, in which asthma and COPD are at the two opposite ends. The prevalence of ACOS varies considerably due to differing criteria being applied for diagnosis. Patients with ACOS utilize a la...
46 CitationsSource
#1Roy A. Pleasants (Duke University)H-Index: 16
#2Tiansheng Wang (PKU: Peking University)H-Index: 18
Last. James F. Donohue (UNC: University of North Carolina at Chapel Hill)H-Index: 48
view all 5 authors...
A number of new agents for the management of chronic obstructive pulmonary disease (COPD) are at different stages of development, including several inhaled long-acting antimuscarinics (LAMA). Long-acting bronchodilators are considered to be central to the management of COPD due to the evidence supporting their efficacy and safety. Umeclidinium, a LAMA, has recently been approved for the maintenance treatment of moderate to very severe COPD in a number of countries. This comprehensive review and ...
21 CitationsSource
#1Yoshihisa IshiuraH-Index: 17
#2Masaki FujimuraH-Index: 53
Last. Kazuo Kasahara (Kanazawa University)H-Index: 28
view all 6 authors...
Abstract Background Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is important because patients with ACOS have significantly worse outcomes compared with those with asthma or chronic obstructive pulmonary disease (COPD) alone. Inhaled corticosteroids (ICS), together with a long-acting β2 agonist (LABA), are recommended, but no therapeutic studies for ACOS have been conducted. Recently, fluticasone furoate/vilanterole (FF/VI) has been approved as the first once-daily ICS/LA...
23 CitationsSource
#1Thomas SilerH-Index: 8
#2Edward KerwinH-Index: 26
Last. Alison Church (RTP: Research Triangle Park)H-Index: 17
view all 6 authors...
Abstract Objective The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added to fluticasone furoate/vilanterol (FF/VI, 100/25 μg) in chronic obstructive pulmonary disease (COPD). Methods These were 12-week, double-blind, placebo-controlled, parallel-group, multicenter studies. Eligible patients were randomized 1:1:1 to treatment with once-daily blinded UMEC 62.5 μg (delivering 55 μg), UMEC 125 μg (delivering 113 μg...
51 CitationsSource
#1Juan-Juan Fu (University of Newcastle)H-Index: 13
#2Peter G. GibsonH-Index: 119
Last. Vanessa M. McDonaldH-Index: 35
view all 4 authors...
Background: The progression of obstructive airway diseases (OADs) including asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap syndrome in older adults is not well understood. Objective: To examine the prognosis of OADs and to identify potential determinants for longitudinal changes in clinical outcomes. Methods: We consecutively recruited 99 older adults (>55 years) with OADs who underwent a multidimensional assessment at baseline and 4 years which involved spirometry,...
67 CitationsSource
Cited By15
Newest
#1Lisa H Y Kim (McMaster University)
#2Carol Saleh (McMaster University)H-Index: 2
Last. Derek K. Chu (McMaster University)H-Index: 25
view all 5 authors...
Importance The benefits and harms of adding long-acting muscarinic antagonists (LAMAs) to inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) for moderate to severe asthma remain unclear. Objective To systematically synthesize the outcomes and adverse events associated with triple therapy (ICS, LABA, and LAMA) vs dual therapy (ICS plus LABA) in children and adults with persistent uncontrolled asthma. Data Sources MEDLINE, Embase, CENTRAL, ICTRP, FDA, and EMA databases from November...
Source
Source
Objective null This real world study evaluated the effectiveness of switching to closed triple therapy from mono/dual combination or open triple therapy in patients with chronic obstructive pulmonary disease (COPD). null Methods null We conducted this retrospective study at a single medical center from December 2014 to September 2020. Patients with COPD who were stepped up to triple therapy were enrolled. We analyzed the duration from initial COPD management to open or closed triple therapy and ...
Source
#1So Young Park (Konkuk University)H-Index: 16
#2Solmi Kim (UOU: University of Ulsan)H-Index: 1
Last. Ga-Young BanH-Index: 16
view all 39 authors...
Background Current guidelines for the treatment of asthma and chronic obstructive pulmonary disease overlap (ACO) recommend initial treatment using inhaled corticosteroids (ICSs) plus 1 or more bronchodilators. Objective To clarify which therapeutic effect is better between the ICS + long-acting β2 agonist (LABA) and ICS + LABA + long-acting muscarinic antagonist (LAMA) treatment in patients with ACO. Methods We conducted a multicenter, 48-week, randomized, noninferiority trial. Patients with AC...
1 CitationsSource
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease associated with significant morbidity and mortality. Over the past few years, there has been cumulating interest in describing this heterogeneity and using this information to group patients into different COPD phenotypes. The term phenotype is defined as single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes. It describes also the ...
Source
#1Yael Mauer (Cleveland Clinic)H-Index: 1
#2Rachel Metzger Taliercio (Cleveland Clinic Lerner College of Medicine)H-Index: 1
Asthma is highly prevalent and sometimes deadly, especially in certain groups. The 2019 Global Initiative for Asthma (GINA) guidelines recommend that all asthma patients be treated with inhaled corticosteroids taken daily or as needed; this improves symptoms and outcomes, even in those with mild disease. Further, asthma management requires a stepwise approach, escalating and de-escalating treatment based on symptom control.
4 CitationsSource
#1Timothy E Albertson (UC Davis: University of California, Davis)H-Index: 61
#2Janelle V Pugashetti (UC Davis: University of California, Davis)H-Index: 1
Last. Susan Murin (UC Davis: University of California, Davis)H-Index: 22
view all 5 authors...
INTRODUCTION Asthma is a heterogeneous syndrome with variable phenotypes. Reversible airway obstruction and airway hyper-responsiveness often with an atopic or eosinophilic component is common in the elderly asthmatic. Asthma chronic obstructive pulmonary disease overlap syndrome (ACOS), a combination of atopy-mediated airway hyper-responsiveness and a history of smoking or other environmental noxious exposures, can lead to some fixed airway obstruction and is also common in elderly patients. Li...
1 CitationsSource
#2Carmela Belardo (Seconda Università degli Studi di Napoli)H-Index: 12
Last. Mario Cazzola (University of Rome Tor Vergata)H-Index: 68
view all 5 authors...
Introduction: The critical role of acetylcholine in asthma pathophysiology and the increase in vagal tone are the main reasons why a LAMA is a good choice in the treatment of the asthmatic patient. Tiotropium is the only LAMA approved for use in asthma in many countries but there is a real interest in developing novel LAMAs for the treatment of asthma, or at least to extend this indication to other LAMAs already on the market.Areas covered: Trials that have studied or are evaluating the role of ...
1 CitationsSource
INTRODUCTION: Bronchial thermoplasty (BT) improves asthma-related quality of life and decreases the number of asthma exacerbations. However, the effectiveness of BT in the treatment of severe asthma with smoking history is unclear because previous studies have excluded patients with smoking history of more than 10 pack-years. OBJECTIVE: The aim of the study was to clarify the effectiveness and safety of BT for severe asthma with smoking history. METHODS: We retrospectively reviewed patients who ...
Source
#2Carmela Belardo (Seconda Università degli Studi di Napoli)H-Index: 12
Last. Mario Cazzola (University of Rome Tor Vergata)H-Index: 68
view all 5 authors...
Introduction: Tiotropium is useful in the presence of severe uncontrolled asthma despite the optimization of therapy with inhaled corticosteroids (ICSs) and long-acting beta2 agonists (LABAs) as recommended by the current guidelines. However, in recent years there has been some further preclinical and clinical evidence on the pharmacological and therapeutic impact of these agents.Areas covered: We have conducted an extensive search on muscarinic antagonists in asthma therapy throughout several s...
Source